WO2022216094A1 - Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 - Google Patents
Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 Download PDFInfo
- Publication number
- WO2022216094A1 WO2022216094A1 PCT/KR2022/005070 KR2022005070W WO2022216094A1 WO 2022216094 A1 WO2022216094 A1 WO 2022216094A1 KR 2022005070 W KR2022005070 W KR 2022005070W WO 2022216094 A1 WO2022216094 A1 WO 2022216094A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- compound
- methyl
- chloro
- mmol
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 24
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 title abstract description 6
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 title description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 125
- 150000003839 salts Chemical class 0.000 claims abstract description 27
- 208000030159 metabolic disease Diseases 0.000 claims abstract description 8
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 5
- 208000008589 Obesity Diseases 0.000 claims abstract description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 4
- 235000020824 obesity Nutrition 0.000 claims abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 76
- -1 oxytanylmethyl Chemical group 0.000 claims description 50
- 125000000217 alkyl group Chemical group 0.000 claims description 37
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 27
- 229910052757 nitrogen Inorganic materials 0.000 claims description 27
- 229910052799 carbon Inorganic materials 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 9
- 229910052763 palladium Inorganic materials 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 8
- 150000003973 alkyl amines Chemical class 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 238000006482 condensation reaction Methods 0.000 claims description 6
- 238000005859 coupling reaction Methods 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 6
- 125000002560 nitrile group Chemical group 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 5
- 229910052805 deuterium Inorganic materials 0.000 claims description 5
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 208000013016 Hypoglycemia Diseases 0.000 claims description 4
- 229910052801 chlorine Inorganic materials 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010020772 Hypertension Diseases 0.000 claims description 3
- LASLVGACQUUOEB-UHFFFAOYSA-N bicyclo[1.1.0]butane Chemical group C1C2CC21 LASLVGACQUUOEB-UHFFFAOYSA-N 0.000 claims description 3
- MKCBRYIXFFGIKN-UHFFFAOYSA-N bicyclo[1.1.1]pentane Chemical group C1C2CC1C2 MKCBRYIXFFGIKN-UHFFFAOYSA-N 0.000 claims description 3
- JSMRMEYFZHIPJV-UHFFFAOYSA-N bicyclo[2.1.1]hexane Chemical group C1C2CC1CC2 JSMRMEYFZHIPJV-UHFFFAOYSA-N 0.000 claims description 3
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical group C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 claims description 3
- 229910052794 bromium Inorganic materials 0.000 claims description 3
- 208000029078 coronary artery disease Diseases 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 208000016097 disease of metabolism Diseases 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 230000003301 hydrolyzing effect Effects 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- UMRZSTCPUPJPOJ-UHFFFAOYSA-N norbornane Chemical group C1CC2CCC1C2 UMRZSTCPUPJPOJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- ABADUMLIAZCWJD-UHFFFAOYSA-N 1,3-dioxole Chemical group C1OC=CO1 ABADUMLIAZCWJD-UHFFFAOYSA-N 0.000 claims description 2
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000002249 Diabetes Complications Diseases 0.000 claims description 2
- 206010012655 Diabetic complications Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims description 2
- 208000004930 Fatty Liver Diseases 0.000 claims description 2
- 208000002705 Glucose Intolerance Diseases 0.000 claims description 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 2
- 206010022489 Insulin Resistance Diseases 0.000 claims description 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 230000005856 abnormality Effects 0.000 claims description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 230000023555 blood coagulation Effects 0.000 claims description 2
- 208000020832 chronic kidney disease Diseases 0.000 claims description 2
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims description 2
- 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 2
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 208000010643 digestive system disease Diseases 0.000 claims description 2
- 208000010706 fatty liver disease Diseases 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims description 2
- 208000024557 hepatobiliary disease Diseases 0.000 claims description 2
- 208000019423 liver disease Diseases 0.000 claims description 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 125000006223 tetrahydrofuranylmethyl group Chemical group 0.000 claims description 2
- 125000006173 tetrahydropyranylmethyl group Chemical group 0.000 claims description 2
- 230000007062 hydrolysis Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 102000018658 Myotonin-Protein Kinase Human genes 0.000 abstract description 3
- 108010052185 Myotonin-Protein Kinase Proteins 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 117
- 238000002360 preparation method Methods 0.000 description 108
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 88
- 238000006243 chemical reaction Methods 0.000 description 78
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 62
- 235000019439 ethyl acetate Nutrition 0.000 description 58
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 51
- 238000000605 extraction Methods 0.000 description 38
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 37
- 238000005481 NMR spectroscopy Methods 0.000 description 37
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 32
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 31
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- 238000000746 purification Methods 0.000 description 29
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 26
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 25
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 16
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 13
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 13
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- 239000012044 organic layer Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 6
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 6
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 5
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 5
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 5
- GIMYFUYQHDSODF-UHFFFAOYSA-N OC(CC(C=C1)=CC=C1C1=CC=CN=C1OCC(C=CC(Cl)=C1)=C1F)=O Chemical compound OC(CC(C=C1)=CC=C1C1=CC=CN=C1OCC(C=CC(Cl)=C1)=C1F)=O GIMYFUYQHDSODF-UHFFFAOYSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- FKMZNQQOPCCUTD-UHFFFAOYSA-N methyl 3-fluoro-4-nitrobenzoate Chemical compound COC(=O)C1=CC=C([N+]([O-])=O)C(F)=C1 FKMZNQQOPCCUTD-UHFFFAOYSA-N 0.000 description 5
- LOKYZYLRFLWOEU-UHFFFAOYSA-N methyl 4-amino-3-(1,3-oxazol-5-ylmethylamino)benzoate Chemical compound NC1=C(C=C(C(=O)OC)C=C1)NCC1=CN=CO1 LOKYZYLRFLWOEU-UHFFFAOYSA-N 0.000 description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- HNFOXZBCUXJBJM-UHFFFAOYSA-N 4-bicyclo[2.2.2]octanylmethanol Chemical compound C1CC2CCC1(CO)CC2 HNFOXZBCUXJBJM-UHFFFAOYSA-N 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000007810 chemical reaction solvent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 150000002430 hydrocarbons Chemical group 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- FXELLBQNJIKREQ-UHFFFAOYSA-N methyl 4-amino-3-[(3-ethylimidazol-4-yl)methylamino]benzoate Chemical compound NC1=C(C=C(C(=O)OC)C=C1)NCC1=CN=CN1CC FXELLBQNJIKREQ-UHFFFAOYSA-N 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Substances [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- VAUXCNRGIOQQGM-UHFFFAOYSA-N COC(CC(C=C1)=CC=C1C1=CC=CN=C1F)=O Chemical compound COC(CC(C=C1)=CC=C1C1=CC=CN=C1F)=O VAUXCNRGIOQQGM-UHFFFAOYSA-N 0.000 description 3
- QREKNDYHKUNPLH-UHFFFAOYSA-N COC(CC(C=C1)=CC=C1C1=NC(OCC2(CC3)CCC3CC2)=CC=C1)=O Chemical compound COC(CC(C=C1)=CC=C1C1=NC(OCC2(CC3)CCC3CC2)=CC=C1)=O QREKNDYHKUNPLH-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- MULIKWHWAGXLAS-UHFFFAOYSA-N ClC1=CC=CC(OCC2(CC3)CCC3CC2)=N1 Chemical compound ClC1=CC=CC(OCC2(CC3)CCC3CC2)=N1 MULIKWHWAGXLAS-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- IUYKVMDWYPDJHQ-UHFFFAOYSA-N NC1=C(C=C(C(=O)OC)C=C1)NCC1=NN=CN1CCC Chemical compound NC1=C(C=C(C(=O)OC)C=C1)NCC1=NN=CN1CCC IUYKVMDWYPDJHQ-UHFFFAOYSA-N 0.000 description 3
- PBCRUVPJWNSSCK-JTQLQIEISA-N NC1=C(C=C(C(=O)OC)C=C1)NC[C@H]1OCCC1 Chemical compound NC1=C(C=C(C(=O)OC)C=C1)NC[C@H]1OCCC1 PBCRUVPJWNSSCK-JTQLQIEISA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- ITKAKYORCHZDMP-UHFFFAOYSA-N [N+](=O)([O-])C1=C(C=C(C(=O)OC)C=C1)NCC1=NN=CN1CCC Chemical compound [N+](=O)([O-])C1=C(C=C(C(=O)OC)C=C1)NCC1=NN=CN1CCC ITKAKYORCHZDMP-UHFFFAOYSA-N 0.000 description 3
- GFVAHDDKWLGFAF-JTQLQIEISA-N [N+](=O)([O-])C1=C(C=C(C(=O)OC)C=C1)NC[C@H]1OCCC1 Chemical compound [N+](=O)([O-])C1=C(C=C(C(=O)OC)C=C1)NC[C@H]1OCCC1 GFVAHDDKWLGFAF-JTQLQIEISA-N 0.000 description 3
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- XNILAPCHEAOFQR-UHFFFAOYSA-N methyl 3-[(3-ethylimidazol-4-yl)methylamino]-4-nitrobenzoate Chemical compound C(C)N1C=NC=C1CNC=1C=C(C(=O)OC)C=CC=1[N+](=O)[O-] XNILAPCHEAOFQR-UHFFFAOYSA-N 0.000 description 3
- YUBBGZUEOCQFQQ-UHFFFAOYSA-N methyl 4-nitro-3-(1,3-oxazol-5-ylmethylamino)benzoate Chemical compound [N+](=O)([O-])C1=C(C=C(C(=O)OC)C=C1)NCC1=CN=CO1 YUBBGZUEOCQFQQ-UHFFFAOYSA-N 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010011459 Exenatide Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010019598 Liraglutide Proteins 0.000 description 2
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 2
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- WQSOSZOUVKKHSA-UHFFFAOYSA-N OC(CC(C=C1)=CC=C1C1=NC(OCC2(CC3)CCC3CC2)=CC=C1)=O Chemical compound OC(CC(C=C1)=CC=C1C1=NC(OCC2(CC3)CCC3CC2)=CC=C1)=O WQSOSZOUVKKHSA-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- OGWAVGNOAMXIIM-UHFFFAOYSA-N albiglutide Chemical compound O=C(O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)CNC(=O)C(NC(=O)CNC(=O)C(N)CC=1(N=CNC=1))CCC(=O)O)C(O)C)CC2(=CC=CC=C2))C(O)C)CO)CC(=O)O)C(C)C)CO)CO)CC3(=CC=C(O)C=C3))CC(C)C)CCC(=O)O)CCC(=O)N)C)C)CCCCN)CCC(=O)O)CC4(=CC=CC=C4))C(CC)C)C)CC=6(C5(=C(C=CC=C5)NC=6)))CC(C)C)C(C)C)CCCCN)CCCNC(=N)N OGWAVGNOAMXIIM-UHFFFAOYSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 108010005794 dulaglutide Proteins 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 125000000336 imidazol-5-yl group Chemical group [H]N1C([H])=NC([H])=C1[*] 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 108010004367 lixisenatide Proteins 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 108700027806 rGLP-1 Proteins 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 108010060325 semaglutide Proteins 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JQXXUBCHSZSDDG-UHFFFAOYSA-N (3-ethylimidazol-4-yl)methanamine;dihydrochloride Chemical compound Cl.Cl.CCN1C=NC=C1CN JQXXUBCHSZSDDG-UHFFFAOYSA-N 0.000 description 1
- XUZRWKWJKDCQNA-UHFFFAOYSA-N (4-chloro-2-fluorophenyl)methanol Chemical compound OCC1=CC=C(Cl)C=C1F XUZRWKWJKDCQNA-UHFFFAOYSA-N 0.000 description 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- GWGCSOXRJFLPEH-UHFFFAOYSA-N 1,3-oxazol-5-ylmethanamine;hydrochloride Chemical compound Cl.NCC1=CN=CO1 GWGCSOXRJFLPEH-UHFFFAOYSA-N 0.000 description 1
- OIGMDNONQJGUCF-UHFFFAOYSA-N 1-(4-chloro-2-fluorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C=C1F OIGMDNONQJGUCF-UHFFFAOYSA-N 0.000 description 1
- FILKGCRCWDMBKA-UHFFFAOYSA-N 2,6-dichloropyridine Chemical compound ClC1=CC=CC(Cl)=N1 FILKGCRCWDMBKA-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- LGCYVLDNGBSOOW-UHFFFAOYSA-N 2H-benzotriazol-4-ol 1-hydroxybenzotriazole Chemical compound OC1=CC=CC2=C1N=NN2.C1=CC=C2N(O)N=NC2=C1 LGCYVLDNGBSOOW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- KESUTBOSNOHAMK-UHFFFAOYSA-N 3-bromo-2-fluoropyridine Chemical compound FC1=NC=CC=C1Br KESUTBOSNOHAMK-UHFFFAOYSA-N 0.000 description 1
- JPBDMIWPTFDFEU-UHFFFAOYSA-N 3-bromobenzene-1,2-diol Chemical compound OC1=CC=CC(Br)=C1O JPBDMIWPTFDFEU-UHFFFAOYSA-N 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 1
- COYPLDIXZODDDL-UHFFFAOYSA-N 3h-benzimidazole-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2N=CNC2=C1 COYPLDIXZODDDL-UHFFFAOYSA-N 0.000 description 1
- UDUGWXQKDABZNV-UHFFFAOYSA-N 4-propyl-1,2,4-triazole Chemical compound CCCN1C=NN=C1 UDUGWXQKDABZNV-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- MIRLPWMMNBLXLJ-UHFFFAOYSA-N CCCN1C(CNC(C=C(C=C2)C(OC)=O)=C2NC(CC(C=C2)=CC=C2C2=CC=CN=C2OCC(C=CC(Cl)=C2)=C2F)=O)=NN=C1 Chemical compound CCCN1C(CNC(C=C(C=C2)C(OC)=O)=C2NC(CC(C=C2)=CC=C2C2=CC=CN=C2OCC(C=CC(Cl)=C2)=C2F)=O)=NN=C1 MIRLPWMMNBLXLJ-UHFFFAOYSA-N 0.000 description 1
- PWXZDWWYFFKDOK-UHFFFAOYSA-N COC(C(C=C1)=CC(NCC2=CN=CO2)=C1NC(CC(C=C1)=CC=C1C1=CC=CN=C1OCC(C=CC(Cl)=C1)=C1F)=O)=O Chemical compound COC(C(C=C1)=CC(NCC2=CN=CO2)=C1NC(CC(C=C1)=CC=C1C1=CC=CN=C1OCC(C=CC(Cl)=C1)=C1F)=O)=O PWXZDWWYFFKDOK-UHFFFAOYSA-N 0.000 description 1
- KBRSORPCZYQDRW-UHFFFAOYSA-N COC(CC(C=C1)=CC=C1C1=CC=CN=C1OCC(C=CC(Cl)=C1)=C1F)=O Chemical compound COC(CC(C=C1)=CC=C1C1=CC=CN=C1OCC(C=CC(Cl)=C1)=C1F)=O KBRSORPCZYQDRW-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YNOGYQAEJGADFJ-YFKPBYRVSA-N [(2s)-oxolan-2-yl]methanamine Chemical compound NC[C@@H]1CCCO1 YNOGYQAEJGADFJ-YFKPBYRVSA-N 0.000 description 1
- 125000005595 acetylacetonate group Chemical group 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 229940049445 adlyxin Drugs 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 229960004733 albiglutide Drugs 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- QKWLQWFMFQOKET-UHFFFAOYSA-N basketane Chemical compound C1CC2C3C4C1C1C4C3C21 QKWLQWFMFQOKET-UHFFFAOYSA-N 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000005347 biaryls Chemical group 0.000 description 1
- PUNFICOCZAPAJV-UHFFFAOYSA-N bicyclo[2.2.2]octane-4-carboxylic acid Chemical compound C1CC2CCC1(C(=O)O)CC2 PUNFICOCZAPAJV-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940084891 byetta Drugs 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- FWXAUDSWDBGCMN-ZEQRLZLVSA-N chiraphos Chemical compound C=1C=CC=CC=1P([C@@H](C)[C@H](C)P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 FWXAUDSWDBGCMN-ZEQRLZLVSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- SINKOGOPEQSHQD-UHFFFAOYSA-N cyclopentadienide Chemical class C=1C=C[CH-]C=1 SINKOGOPEQSHQD-UHFFFAOYSA-N 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- QKZWXPLBVCKXNQ-ROJLCIKYSA-N dipamp Chemical compound COC1=CC=CC=C1[P@@](C=1C=CC=CC=1)CC[P@@](C=1C(=CC=CC=1)OC)C1=CC=CC=C1 QKZWXPLBVCKXNQ-ROJLCIKYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 229960005175 dulaglutide Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- NBPODFADVLNXKO-UHFFFAOYSA-N methyl 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetate Chemical compound C1=CC(CC(=O)OC)=CC=C1B1OC(C)(C)C(C)(C)O1 NBPODFADVLNXKO-UHFFFAOYSA-N 0.000 description 1
- CEYHKCZODRRMMV-VIFPVBQESA-N methyl 4-amino-3-[[(2S)-oxetan-2-yl]methylamino]benzoate Chemical compound NC1=C(C=C(C(=O)OC)C=C1)NC[C@H]1OCC1 CEYHKCZODRRMMV-VIFPVBQESA-N 0.000 description 1
- HTYWVEUBCLGQES-VIFPVBQESA-N methyl 4-nitro-3-[[(2S)-oxetan-2-yl]methylamino]benzoate Chemical compound [N+](=O)([O-])C1=C(C=C(C(=O)OC)C=C1)NC[C@H]1OCC1 HTYWVEUBCLGQES-VIFPVBQESA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- LQEXPHILFYMEJR-UHFFFAOYSA-N methylazanium dichloride Chemical compound Cl.Cl.NC.NC LQEXPHILFYMEJR-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 150000003003 phosphines Chemical class 0.000 description 1
- RLOWWWKZYUNIDI-UHFFFAOYSA-N phosphinic chloride Chemical compound ClP=O RLOWWWKZYUNIDI-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229950011186 semaglutide Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940035447 tanzeum Drugs 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- PHCBRBWANGJMHS-UHFFFAOYSA-J tetrasodium;disulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O PHCBRBWANGJMHS-UHFFFAOYSA-J 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 229940013051 trulicity Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940007428 victoza Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Definitions
- the present invention relates to a novel compound exhibiting GLP-1 receptor agonist activity, an isomer thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound, and a method for preparing the compound.
- Glucagon-like peptide-1 is a polypeptide hormone secreted by intestinal L-cells after a meal and can stimulate insulin secretion from pancreatic islet ⁇ cells, thereby stabilizing postprandial blood glucose levels.
- This GLP-1 binds to the GLP-1 receptor (GLP-1R).
- GLP-1R GLP-1 receptor
- the GLP-1 receptor is a protein belonging to the Class B receptor subclass of G protein-coupled receptors (GPCRs) that regulate important physiological and pathophysiological processes. Since it has a unique binding method that determines affinity by binding to a ligand, it is recognized as a very difficult drug target to develop a low-molecular-weight synthetic ligand.
- GLP-1 normalizes blood glucose levels in patients with type 2 diabetes. Since the effect of GLP-1 on lowering blood sugar levels depends on the glucose concentration, it greatly reduces the risk of hypoglycemia while controlling blood sugar levels. Also, byetta ® and Bydureon BCise ® (exenatide), Ozempic ® (semaglutide), Victoza ® (liraglutide), Adlyxin ® (lixisenatide); Drugs based on GLP-1, such as Tanzeum ® (albiglutide), and Trulicity ® (dulaglutide), are GLP-1 receptor agonists and have been successfully marketed in recent years, such as For example, it has been found to provide effective glycemic control for the treatment of type 2 diabetes mellitus, in addition to providing a weight loss effect, preservation of beta-cell function and alleviation of hypertension, hypoglycemia and/or hyperlipidemia.
- GLP-1 and GLP-1 receptor agonists may lack sufficient oral bioavailability to be considered as a peptide-based oral drug. demand exists.
- the present invention provides a novel compound having activity as a GLP-1 agonist.
- the present invention is to provide a pharmaceutical composition for preventing or treating metabolic diseases or neurodegenerative diseases comprising the novel compound as an active ingredient.
- each group used herein will be described in detail. Unless otherwise specified, each group has the following definitions.
- halo may be fluoro, chloro, bromo or iodo.
- alkyl refers to a linear or branched aliphatic saturated hydrocarbon group, and specifically, it may be C 1 to 6 carbon atoms, that is, C 1-6 alkyl, C 1-4 alkyl, or C 1-3 alkyl.
- alkyls examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, 1-ethylpropyl, hexyl, isohexyl, 1,1-dimethyl butyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl or 2-ethylbutyl.
- alkoxy refers to an oxygen group to which a single-bonded straight-chain or branched saturated hydrocarbon is bonded, and may specifically be C 1-6 alkoxy, C 1-4 alkoxy, or C 1-3 alkoxy. Examples of such alkoxy may be methoxy, ethoxy, propoxy, n-butoxy, tert-butoxy or 1-methylpropoxy.
- cycloalkyl refers to a saturated hydrocarbon group of a single cyclic bond, and specifically, may be C 3-8 cycloalkyl or C 3-6 cycloalkyl depending on the number of carbon atoms. Examples of such cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.
- cycloalkyl may be a fused or bridged of two or more cycloalkyls, specifically, a bridged bi-cycloalkyl, a bridged tri-cycloalkyl, prismain, It may encompass prismaines and asteranes such as cubane, basketane, and the like, and examples of such cross-linked cycloalkyls include bicyclo[1,1,0] butane, bicyclo[1,1,1]pentane, bicyclo[2,1,1]hexane, bicyclo[2,2,1]heptane, bicyclo[2,2,2]octane, and the like.
- heterocycloalkyl refers to a saturated hydrocarbon group of a single cyclic bond containing at least one heteroatom such as N, O, or S in addition to a carbon atom as a ring member, and is a monocyclic or fused ring poly Specifically, 4- to 10-membered-heterocycloalkyl, 4-membered containing one or more, preferably 1-3, heteroatoms selected from the group consisting of N, O and S - to 7 membered heterocycloalkyl, or 4 to 6 membered heterocycloalkyl Examples of such heterocycloalkyl include oxytanyl, aziridine, pyrrolidine, pyrrolidinyl, piperidinyl, pyr perazinyl, morpholinyl, tetrahydrofuranyl or tetrahydropyranyl;
- aryl refers to an aromatic substituent having at least one ring having a shared pi electron system, and may be monocyclic or fused ring polycyclic (ie, rings having adjacent pairs of carbon atoms). can Specifically, the aryl may be C 4-10 aryl or C 6-10 aryl, depending on the number of carbon atoms included in the ring, for example, phenyl or naphthyl.
- heteroaryl refers to an aromatic ring compound including at least one heteroatom such as N, O, or S in addition to a carbon atom as a ring member, and may be monocyclic or fused-ring polycyclic. Specifically, 4- to 10-membered-heteroaryl, 4- to 7-membered-heteroaryl containing at least one, preferably 1 to 3 heteroatoms selected from the group consisting of N, O and S , or 4- to 6-membered-heteroaryl.
- heteroaryl examples include furanyl, pyranyl, imidazolyl, oxazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidyl, pyridazinyl, oxadiazolyl, thiadiazolyl, tetrazolyl, triazinyl, Although triazyl, triazolyl, etc. are mentioned, It is not limited only to these.
- the "substituent” may be at least one selected from the group consisting of halo, a nitrile group, and a C 1-3 alkyl group.
- the present invention provides a compound of formula (I), an isomer thereof, or a pharmaceutically acceptable salt thereof.
- A is -(CH 2 ) m -, -O- or -N(R a )-, wherein m is an integer from 1 to 3 and R a is hydrogen or alkyl;
- Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 each independently represents CH, CF, CCl, CBr, CI or N;
- Z 8 or Z 9 are each independently C or N substituted with an —O—CH 2 —R group, or when Z 8 and Z 9 are both C, each substituent may be condensed with each other to form a dioxol structure;
- R is cycloalkyl or ego
- R 1 is (cycloalkyl)alkyl, (heterocycloalkyl)alkyl, (aryl)alkyl or (heteroaryl)alkyl;
- R 2 , R 3 or R 4 are each independently a hydrogen, deuterium, halo, alkyl, alkoxy, alkylamine or nitrile group;
- n 1 to n 3 are each independently an integer of 1 to 4, wherein, when n 1 to n 3 is an integer of 2 or more, each of R 2 , R 3 or R 4 may be the same as or different from each other;
- alkyl, alkoxy, alkylamine, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl is unsubstituted or substituted.
- the compound of Formula I may be a compound represented by Formula 1, Formula 1', or Formula 1”, an isomer thereof, or a pharmaceutically acceptable salt thereof:
- A, Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 , Z 7 , R, R 1 , R 2 , R 3 , R 4 and n 1 to n 3 are as defined in claim 1 . .
- A may be -CH 2 -, -O- or -N(R a )-.
- R a may be hydrogen or C 1-3 alkyl.
- R is C 3-8 -cycloalkyl or and C 3-8 cycloalkyl may be bridged or unbridged cycloalkyl, and may include, but is not limited to, mono-, bi-, poly- and bridged ring systems.
- R 1 is (C 3-8 cycloalkyl)C 1-3 alkyl, (4- to 10-membered-heterocycloalkyl)C 1-3 alkyl, (C 6-10 aryl)alkyl or (4 One- to 10-membered-heteroaryl)C 1-3 alkyl, wherein the heterocycloalkyl or heteroaryl includes one to three heteroatoms selected from the group consisting of N, O and S .
- R 2 , R 3 or R 4 are each independently hydrogen, deuterium, F, Cl, Br, I, C 1-3 alkyl, C 1-3 alkoxy, C 1-3 alkylamine or nitrile group.
- n 1 to n 3 are each independently an integer of 1 to 3, wherein, when n 1 to n 3 is an integer of 2 or more, each of R 2 , R 3 or R 4 may be the same as or different from each other.
- Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 or Z 7 can each independently be CH, CF or CCl.
- the alkyl, alkoxy, alkylamine, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl may be unsubstituted or substituted with halo or C 1-3 alkyl.
- A may be —CH 2 — or —O—.
- R is bicyclo[1,1,0]butane, bicyclo[1,1,1]pentane, bicyclo[2,1,1]hexane, bicyclo[2,2,1]heptane , bicyclo[2,2,2]octane or can be
- R 1 is cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, oxytanylmethyl, tetrahydrofuranylmethyl, tetrahydropyranylmethyl, oxazolylmethyl, benzyl, unsubstituted or triazolylmethyl substituted with propyl or imidazolylmethyl unsubstituted or substituted with ethyl.
- R 2 , R 3 or R 4 are each independently hydrogen, deuterium, F, Cl, or a nitrile group.
- n 1 to n 3 are 2, and each of R 2 , R 3 or R 4 may be the same as or different from each other.
- Representative compounds of formula (I) according to the present invention may include, but are not limited to, the following compounds:
- the compounds belonging to the above-mentioned category of Formula I may exhibit excellent GLP-1 receptor agonist activity, and thus exhibit a hypoglycemic action and a positive effect on pancreatic beta cells, so that they can be used more effectively to treat various metabolic diseases.
- the compound represented by the formula (I) may have an asymmetric carbon center, and when it has an asymmetric carbon center, it may exist as individual optical isomers, partial optical isomers or racemates, and all forms of isomers including these are also invented may be included in the category of compounds according to one embodiment of It goes without saying that any form of an isomer may also fall within the scope of the compound of one embodiment.
- the term "isomer” may generically refer to different compounds having the same molecular formula, and “optical isomer” may collectively refer to any stereoisomer that may exist for a compound of one embodiment, including the same geometric isomer. .
- each substituent may be attached to a chiral center of a carbon atom.
- any asymmetric carbon atom on the compound of one embodiment may exist in any form of ( R )-, ( S )- or ( R , S )- configuration, suitably in each isolated form ( R )- or ( S )- configuration.
- the compound of one embodiment may exist in any form of any possible isomer or mixture thereof, for example, any form of pure geometric isomer, diastereomer, optical isomer, racemate or mixtures thereof. can exist as
- each substituent attached to the double bond may be in the E or Z configuration.
- each substituent of the cycloalkyl may have a cis or trans configuration.
- salts refers to any salt that has the same biological effectiveness and properties of the compound of Formula I according to one embodiment, and is desirable from the viewpoint of pharmaceutical, biological or other properties.
- Non-limiting examples of such salts include salts in which an inorganic or organic base is added to the compound of formula (I), or acid addition salts.
- organic acids capable of forming such acid addition salts include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p -toluenesulfonic acid or salicylic acid, and the like, and examples of the inorganic acid include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or phosphoric acid.
- the pharmaceutically acceptable salt of the compound of the above-described embodiment may be synthesized from the free base form of the compound or any basic or acidic moiety derived therefrom by conventional chemical methods.
- a second pharmaceutically acceptable salt may be synthesized from a first pharmaceutically acceptable salt.
- an acid addition salt of a compound of one embodiment can be obtained by reacting a compound in its free base form with a stoichiometric amount of an appropriate acid. In this case, the reaction may be carried out in water, an organic solvent, or a mixture thereof, specifically, in a non-aqueous medium such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile.
- each form of the salt may be obtained by a conventional reaction obvious to those skilled in the art.
- a pharmaceutical composition for the treatment or prevention of metabolic diseases comprising the compound represented by Formula I, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- the compounds represented by Formula I according to the present invention exhibit GLP-1 receptor (GLP-1R) agonistic activity, and a pharmaceutical composition comprising such a compound has effective hypoglycemic action and pancreatic beta cell activity. It can exhibit an effect of improving lipid metabolism, a chronic cardiovascular risk factor, while having a positive effect on effective.
- GLP-1R GLP-1 receptor
- the metabolic disease is diabetes (preferably type 2 diabetes), hypertension, hypoglycemia, hyperlipidemia (dyslipidemia), atherosclerosis, coronary artery disease, cardiovascular disorder (cardiovascular disorder), blood coagulation abnormality, obesity, It may be a disease selected from the group consisting of diabetic complications, diabetic retinopathy, liver disease, hepatobiliary disease, fatty liver, alcoholic steatohepatitis, chronic kidney disease, insulin resistance, and impaired glucose tolerance.
- the neurodegenerative disease may be a disease selected from the group consisting of Parkinson's disease and Alzheimer's disease.
- a pharmaceutical composition containing the compound represented by Formula I, an isomer thereof, or a pharmaceutically used salt thereof as an active ingredient may be used in the form of a conventional pharmaceutical preparation. That is, the pharmaceutical composition may be administered in various oral or parenteral dosage forms during actual clinical administration, and may be appropriately administered in an oral dosage form.
- conventional fillers, extenders, binders, wetting agents, disintegrants, or surfactants such as pharmaceutically acceptable diluents or excipients may be further included in the formulation.
- Solid preparations for oral administration may include tablets, pills, powders, granules, or capsules, and these solid preparations include starch, calcium carbonate, sucrose or lactose, gelatin, etc. may be provided by mixing with the active ingredient.
- a lubricant such as magnesium stearate or talc may be used.
- liquid preparations for oral administration include suspensions, internal solutions, emulsions or syrups, and these liquid preparations include water, which is a simple diluent, or liquid paraffin, but also various excipients, for example, wetting agents, sweeteners, It may contain fragrances or preservatives, and the like.
- preparations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations or suppositories.
- parenteral preparations may include non-aqueous solvents, and as the suspension solutions, vegetable oils such as propylene glycol, polyethylene glycol, olive oil, or injectable esters such as ethyl oleate may be used.
- vegetable oils such as propylene glycol, polyethylene glycol, olive oil, or injectable esters such as ethyl oleate
- As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin, or glycerogelatin may be used.
- the compound represented by the above formula (I) of the pharmaceutical invention containing the present or a pharmaceutically acceptable salt thereof as an active ingredient, an isomer composition thereof may represent an effective amount in an administration range of about 0.1 to about 1,000 mg.
- the dosage or dosage may be administered in various dosages and methods, such as one or several times a day, depending on the patient's weight, age, sex, health status, diet, administration time, administration method, excretion rate, and severity of disease. It is possible.
- the present invention also provides a method for preparing a compound represented by Formula 1, Formula 1' or Formula 1”.
- a compound represented by Formula 1, Formula 1' or Formula 1 can be prepared by arbitrarily combining various synthetic methods described herein or disclosed in the prior art, which will be understood to fall within the scope of the present invention, 1, the method for preparing the compound represented by Chemical Formula 1' or Chemical Formula 1” is not limited to those described below.
- the compound of Formula 1 when A in the compound of Formula 1 according to the present invention is carbon, the compound of Formula 1 may be prepared by a preparation method comprising the following steps:
- step 2) reacting the compound of formula 4 obtained in step 1) with a compound of formula 5 under a palladium catalyst and then hydrolyzing to obtain a compound of formula 6;
- step 3 After the coupling reaction of the compound of Formula 6 with the compound of Formula 7 obtained in step 2), a condensation reaction and hydrolysis reaction to obtain a compound of Formula 1 below.
- the base used in steps 1) and 2) is C 1-4 trialkylamine, diisopropylethyleneamine (DIPEA, Hunig's base), pyridine, K 2 CO 3 , KOH, NaOH, Na 2 CO 3 , NaOAc , Ca(OH) 2 , NaHCO 3 , Cs 2 CO 3 and LiOH may be used alone or in combination, and the ligand used in steps 1) and 2) is triarylphosphines ), trialkylphosphines, biaryl(dialkyl)phosphines, diphosphines, N-heterocyclic carbenes , cyclopentadienides, acetylacetonates, diamines, bipyridines, pyridines, DIOP, DiPAMP, BINAP, chiraphos, etc., but limited thereto it's not going to be
- the hydrolysis reaction of step 2) may be performed using NaOH, KOH, LiOH, etc., and may be carried out at 0 °C to 80 °C, 10 to 70 °C, 20 to 60 °C, or room temperature or 50 °C temperature. , but is not limited thereto.
- the reaction may be performed through stirring for an appropriate time during the reaction, which may be appropriately controlled.
- the compound of Formula 1' when A is carbon in the compound of Formula 1' according to the present invention, the compound of Formula 1' may be prepared by a preparation method comprising the following steps.
- the base, ligand, conditions of the hydrolysis reaction, etc. used in the preparation method may all be applied as described in the preparation method of compound 1.
- the compound of Formula 1" when A in the compound of Formula 1" according to the present invention is carbon, the compound of Formula 1" may be prepared by a manufacturing method comprising the following steps.
- step 2 reacting the compound of Formula 4′ obtained in step 1”) with a compound of Formula 5 below under a palladium catalyst and then hydrolyzing to obtain a compound of Formula 6”;
- step 3 A step of obtaining a compound of Formula 1” through a condensation reaction and a hydrolysis reaction after the coupling reaction of the compound of Formula 6” obtained in step 2”) with the compound of Formula 7 below.
- the base, ligand, conditions of the hydrolysis reaction, etc. used in the preparation method can all be applied as described in the preparation method of compound 1”.
- n 1 , n 2 , n 3 , R a , R, R 1 , R 2 , R 3 , R 4 , Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 and Z 7 are as defined in Formula 1 above;
- R 5 is alkyl
- X is halo, preferably Cl, Br or I.
- a compound not specifically described in the preparation method of the present specification is a compound known per se, or a compound that can be easily synthesized from a known compound by a known synthesis method or a method similar thereto.
- the compound of Formula 1, Formula 1', or Formula 1" obtained through the above method can be isolated or purified from the reaction product by various methods such as recrystallization, iontophoresis, silica gel column chromatography, or ion exchange resin chromatography.
- the compound according to the present invention can be synthesized by various methods, and these methods include the preparation of a compound represented by Chemical Formula 1, Chemical Formula 1' or Chemical Formula 1” and In this regard, it should be construed as being included in the scope of the present invention.
- novel compound according to the present invention is useful as an agent for the treatment or prevention of obesity or various metabolic diseases such as diabetes and hyperlipidemia through excellent GLP-1 agonist activity and excellent DMPK profile.
- HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate
- Methyl 3-(((1-ethyl-1 H -imidazol-5-yl)methyl)amino)-4-nitrobenzoate (440 mg, 1.446 mmol) obtained in Preparation Example 3 was mixed with MeOH/H 2 O ( 6 mL/2 mL), Fe (242 mg, 4.34 mmol) and NH 4 Cl (1.55 g, 28.9 mmol) were added, and the mixture was stirred at 80 °C under nitrogen for 3 hours. After completion of the reaction, after cooling to room temperature, water was added, extracted with EtOAc, dried over MgSO 4 , and concentrated under reduced pressure. MPLC gave methyl 4-amino-3-(((1-ethyl-1 H -imidazol-5-yl)methyl)amino)benzoate (254 mg, 0.925 mmol, 64%).
- 3-bromobenzene-1,2-diol (20 g, 105.814 mmol) was dissolved in toluene (211 mL), and then 1- (4-chloro-2-fluorophenyl) ethan-1-one (19.08 g, 110.576 mmol) and PTSA-H 2 O (402 mg, 2.116 mmol) were added and refluxed under a Dean-Stark trap for 96 hours.
- Bicyclo[2.2.2]octane-1-carboxylic acid (1110 mg, 7.198 mmol) is dissolved in Et 2 O, and LiAH 4 (409 mg, 10.797 mmol) is slowly added at 0 o C. After stirring at room temperature for 1 hour, the temperature is again lowered to 0 o C, and 0.41 mL of water is slowly added. 0.41 mL of 15% NaOH (aq) is added, and 1.23 mL of water is further added, followed by stirring at room temperature for 15 minutes. The aluminum complex was filtered with filter paper and concentrated under reduced pressure to obtain bicyclo[2.2.2]octan-1-ylmethanol (972.8 mg, 6.937 mmol, 96%).
- Example 8 2- (4- (2- (4-chloro-2-fluorophenyl) -2-methylbenzo [ d ][1,3]dioxol-4-yl)benzyl)-1-((4-propyl-4) H -1,2,4-triazol-3-yl)methyl)-1 H -benzo[ d ]Preparation of imidazole-6-carboxylic acid]
- Acetic acid was concentrated under reduced pressure and purified by MPLC, intermediate methyl 2-(4-(2-(4-chloro-2-fluorophenyl)-2-methylbenzo[ d ][1,3]dioxol-4-yl) )benzyl)-1-((( S )-tetrahydrofuran-2-yl)methyl) -1H -benzo[ d ]imidazole-6-carboxylate was obtained.
- the intermediate is dissolved in 5 mL THF, 0.5 mL of 1N NaOH is added to the reaction mixture, and the mixture is stirred at 50 o C for 15 hours. 1N HCl was added to adjust the pH to 4 and extracted with EtOAc.
- the compounds corresponding to Formula 1, Formula 1', or Formula 1" according to the present invention were confirmed to have excellent effects as excellent GLP-1 receptor agonists.
- a compound corresponding to Formula 1 through experiments related to drug metabolism and pharmacokinetics such as Cytochrome P (CYP) inhibition/induction experiments, metabolic stability (MS) experiments, etc. It was confirmed that they had an excellent DMPK profile.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (13)
- 하기 화학식 I의 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염:[화학식 I]A는 -(CH2)m-, -O- 또는 -N(Ra)-이고, 이때 m은 1 내지 3의 정수이고, Ra는 수소 또는 알킬이고;Z1, Z2, Z3, Z4, Z5, Z6 또는 Z7은 각각 독립적으로 CH, CF, CCl, CBr, CI 또는 N을 나타내고;Z8 또는 Z9는 각각 독립적으로 -O-CH2-R기로 치환된 C 또는 N이거나, Z8 및 Z9가 모두 C인 경우 각각의 치환기가 서로 축합되어 다이옥솔 구조를 형성할 수 있고;R1은 (사이클로알킬)알킬, (헤테로사이클로알킬)알킬, (아릴)알킬 또는 (헤테로아릴)알킬이고;R2, R3 또는 R4는 각각 독립적으로 수소, 중수소, 할로, 알킬, 알콕시, 알킬아민 또는 나이트릴기이고;n1 내지 n3은 각각 독립적으로 1 내지 4의 정수이고, 이때, n1 내지 n3이 2 이상의 정수인 경우 각각의 R2, R3 또는 R4는 서로 같거나 다를 수 있고;이때, 상기 알킬, 알콕시, 알킬아민, 사이클로알킬, 헤테로사이클로알킬, 아릴, 또는 헤테로아릴은 비치환되거나 또는 치환된 것이다.
- 제1항에 있어서,상기 A가 -CH2-, -O- 또는 -N(Ra)-이고, 이때, 상기 Ra는 수소 또는 C1-3 알킬인 것인, 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서,상기 R1은 (C3-8 사이클로알킬)C1-3 알킬, (4원- 내지 10원- 헤테로사이클로알킬)C1-3 알킬, (C6-10 아릴)알킬 또는 (4원- 내지 10원- 헤테로아릴)C1-3 알킬일 수 있고, 이때, 상기 헤테로사이클로알킬 또는 헤테로아릴은 N, O 및 S로 이루어진 군으로부터 선택되는 1종 내지 3종의 헤테로원자를 포함하는 것이고;상기 R2, R3 또는 R4는 각각 독립적으로 수소, 중수소, F, Cl, Br, I, C1-3 알킬, C1-3 알콕시, C1-3 알킬아민 또는 나이트릴기이며, n1 내지 n3은 각각 독립적으로 1 내지 3의 정수이고, 이때, n1 내지 n3이 2 이상의 정수인 경우 각각의 R2, R3 또는 R4는 서로 같거나 다를 수 있는 것인, 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서,Z1, Z2, Z3, Z4, Z5, Z6 또는 Z7은 각각 독립적으로 CH, CF 또는 CCl인 것인, 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염.
- 제1항에 있어서,상기 화학식 I로 표시되는 화합물은 하기 화합물들로 이루어진 군으로부터 선택되는 것인, 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염:1] (S)-2-(4-(2-((4-클로로-2-플루오로벤질)옥시)피리딘-3-일)벤질)-1-(옥시탄-2-일메틸)-1H-벤조[d]이미다졸-6-카복실산;2] 2-(4-(2-(4-클로로-2-플루오로페닐)-2-메틸벤조[d][1,3]다이옥솔-4-일)벤질)-1-(((S)-옥시탄-2-일)메틸)-1H-벤조[d]이미다졸-6-카복실산;3] 2-(4-(2-(4-클로로-2-플루오로페닐)-2-메틸벤조[d][1,3]다이옥솔-4-일)-3-플루오로벤질)-1-(((S)-옥시탄-2-일)메틸)-1H-벤조[d]이미다졸-6-카복실산;4] 2-(4-(2-(4-클로로-2-플루오로페닐)-2-메틸벤조[d][1,3]다이옥솔-4-일)벤질)-1-(옥사졸-5-일메틸)-1H-벤조[d]이미다졸-6-카복실산;5] 2-(4-(2-(4-클로로-2-플루오로페닐)-2-메틸벤조[d][1,3]다이옥솔-4-일)-3-플루오로벤질)-1-(옥사졸-5-일메틸)-1H-벤조[d]이미다졸-6-카복실산;6] 2-(4-(2-((4-클로로-2-플루오로벤질)옥시)피리딘-3-일)벤질)-1-(옥사졸-5-일메틸)-1H-벤조[d]이미다졸-6-카복실산;7] 2-(4-(2-((4-클로로-2-플루오로벤질)옥시)피리딘-3-일)벤질)-1-((4-프로필-4H-1,2,4-트리아졸-3-일)메틸)-1H-벤조[d]이미다졸-6-카복실산;8] 2-(4-(2-(4-클로로-2-플루오로페닐)-2-메틸벤조[d][1,3]다이옥솔-4-일)벤질)-1-((4-프로필-4H-1,2,4-트리아졸-3-일)메틸)-1H-벤조[d]이미다졸-6-카복실산;9] 2-(4-(2-(4-클로로-2-플루오로페닐)-2-메틸벤조[d][1,3]다이옥솔-4-일)-3-플루오로벤질)-1-((4-프로필-4H-1,2,4-트리아졸-3-일)메틸)-1H-벤조[d]이미다졸-6-카복실산;10] 2-(4-(2-(4-클로로-2-플루오로페닐)-2-메틸벤조[d][1,3]다이옥솔-4-일)벤질)-1-((1-에틸-1H-이미다졸-5-일)메틸)-1H-벤조[d]이미다졸-6-카복실산;11] 2-(4-(2-(4-클로로-2-플루오로페닐)-2-메틸벤조[d][1,3]다이옥솔-4-일)-3-플루오로벤질)-1-((1-에틸-1H-이미다졸-5-일)메틸)-1H-벤조[d]이미다졸-6-카복실산;12] 2-(4-(2-(4-클로로-2-플루오로페닐)-2-메틸벤조[d][1,3]다이옥솔-4-일)벤질)-1-(((S)-테트라하이드로퓨란-2-일)메틸)-1H-벤조[d]이미다졸-6-카복실산; 및13] (S)-2-(4-(6-(바이싸이클로[2.2.2]옥탄-1-일메톡시)피리딘-2-일)벤질)-1-(옥시탄-2-일메틸)-1H-벤조[d]이미다졸-6-카복실산.
- 제1항 내지 제7항 중 어느 한 항의 화합물, 이의 이성질체 또는 이의 약학적으로 허용가능한 염 및 약학적으로 허용가능한 부형제, 희석제 또는 담체를 포함하는, 대사성 질환 또는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물.
- 제8항에 있어서, 상기 대사성 질환은 당뇨, 고혈압, 저혈당증, 고지혈증(이상지질혈증), 아테롬성 동맥 경화증(atherosclerosis), 관상 동맥 질환(coronary artery disease), 심혈관장애(cardiovascular disorder), 혈액응고 이상, 비만, 당뇨합병증, 당뇨병성 망막병증, 간질환, 간담도질환, 지방간, 알콜성 지방간염, 만성신장질환, 인슐린 저항성 및 내당능장애로 이루어진 군으로부터 선택되는 것인, 약학적 조성물.
- 제8항에 있어서, 상기 퇴행성 신경질환은 파킨슨병 및 알츠하이머로 이루어진 군으로부터 선택되는 것인, 약학적 조성물.
- 1) 하기 화학식 2의 화합물 및 하기 화학식 3의 화합물을 팔라듐 촉매 하에서 반응시켜 하기 화학식 4의 화합물을 수득하는 단계;2) 상기 단계 1)에서 수득된 하기 화학식 4의 화합물을 팔라듐 촉매 하에서 하기 화학식 5의 화합물과 반응시킨 후 가수분해하여 하기 화학식 6의 화합물을 수득하는 단계; 및3) 상기 단계 2)에서 수득된 하기 화학식 6의 화합물과 하기 화학식 7의 화합물의 짝지음 반응 후 축합반응과 가수분해반응을 통해 하기 화학식 1의 화합물을 수득하는 단계,를 포함하는 하기 화학식 1의 화합물의 제조방법:[화학식 1][화학식 2][화학식 3][화학식 4][화학식 5][화학식 6][화학식 7]상기 식에서,A는 탄소이고;n1, n2, n3, R, R1, R2, R3, R4, Z1, Z2, Z3, Z4, Z5, Z6 및 Z7는 제1항에서 정의한 바와 같고;R5는 알킬이고;X는 할로이다.
- 1') 하기 화학식 3'의 화합물을 팔라듐 촉매 하에서 하기 화학식 5의 화합물과 반응시켜 하기 화학식 8의 화합물을 수득하는 단계;2') 상기 단계 1')에서 수득된 하기 화학식 8의 화합물을 하기 화학식 2의 화합물과 반응시켜 하기 화학식 6'의 화합물을 수득하는 단계; 및3') 상기 단계 2')에서 수득된 하기 화학식 6'의 화합물과 하기 화학식 7의 화합물의 짝지음 반응 후 축합반응과 가수분해반응을 통해 하기 화학식 1'의 화합물을 수득하는 단계,를 포함하는 하기 화학식 1'의 화합물의 제조방법:[화학식 1'][화학식 2][화학식 3'][화학식 5][화학식 6'][화학식 7][화학식 8]상기 식에서,A는 탄소이고;n1, n2, n3, R, R1, R2, R3, R4, Z1, Z2, Z3, Z4, Z5, Z6 및 Z7는 제1항에서 정의한 바와 같고;R5는 알킬이고;X는 할로이다.
- 1”) 하기 화학식 2'의 화합물을 하기 화학식 3”의 화합물과 반응시켜 하기 화학식 4'의 화합물을 수득하는 단계;2”) 상기 단계 1”)에서 수득된 하기 화학식 4'의 화합물을 팔라듐 촉매 하에서 하기 화학식 5의 화합물과 반응시킨 후 가수분해하여 하기 화학식 6”의 화합물을 수득하는 단계; 및3”) 상기 단계 2”)에서 수득된 하기 화학식 6”의 화합물과 하기 화학식 7의 화합물의 짝지음 반응 후 축합반응과 가수분해반응을 통해 하기 화학식 1”의 화합물을 수득하는 단계,를 포함하는 하기 화학식 1”의 화합물의 제조방법:[화학식 1”][화학식 2'][화학식 3”][화학식 4'][화학식 5][화학식 6”][화학식 7]상기 식에서,A는 탄소이고;n1, n2, n3, R, R1, R2, R3, R4, Z1, Z2, Z3, Z4, Z5, Z6 및 Z7는 제1항에서 정의한 바와 같고;R5는 알킬이고;X는 할로이다.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP22785003.9A EP4303215A4 (en) | 2021-04-08 | 2022-04-07 | GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION COMPRISING IT AND PREPARATION METHOD THEREOF |
US18/554,345 US20240300928A1 (en) | 2021-04-08 | 2022-04-07 | Glp-1 receptor agonist, pharmaceutical composition comprising same, and method for preparing same |
JP2023561836A JP2024514259A (ja) | 2021-04-08 | 2022-04-07 | Glp-1受容体作動薬、それを含む薬学的組成物、およびその製造方法 |
CN202280026710.4A CN117279904A (zh) | 2021-04-08 | 2022-04-07 | Glp-1受体激动剂、包含其的药物组合物及其制备方法 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2021-0046024 | 2021-04-08 | ||
KR20210046024 | 2021-04-08 | ||
KR10-2022-0043280 | 2022-04-07 | ||
KR1020220043280A KR20220140429A (ko) | 2021-04-08 | 2022-04-07 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022216094A1 true WO2022216094A1 (ko) | 2022-10-13 |
Family
ID=83546540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/005070 WO2022216094A1 (ko) | 2021-04-08 | 2022-04-07 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20240300928A1 (ko) |
JP (1) | JP2024514259A (ko) |
WO (1) | WO2022216094A1 (ko) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114630823A (zh) * | 2019-10-25 | 2022-06-14 | 吉利德科学公司 | Glp-1r调节化合物 |
WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
US11897851B2 (en) | 2020-08-06 | 2024-02-13 | Gasherbrum Bio, Inc. | Heterocyclic GLP-1 agonists |
US11926626B2 (en) | 2020-08-28 | 2024-03-12 | Gasherbrum Bio, Inc. | Heterocyclic GLP-1 agonists |
WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
WO2024107781A1 (en) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
US12091404B2 (en) | 2021-03-11 | 2024-09-17 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018183112A1 (en) * | 2017-03-27 | 2018-10-04 | Cardurion Pharmaceuticals, Llc | Heterocyclic compound |
WO2020207474A1 (en) * | 2019-04-12 | 2020-10-15 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
WO2020263695A1 (en) * | 2019-06-28 | 2020-12-30 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
KR20210020095A (ko) * | 2018-06-15 | 2021-02-23 | 화이자 인코포레이티드 | Glp-1 수용체 효능제 및 그의 용도 |
WO2021154796A1 (en) * | 2020-01-29 | 2021-08-05 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
WO2021187886A1 (ko) * | 2020-03-18 | 2021-09-23 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
-
2022
- 2022-04-07 JP JP2023561836A patent/JP2024514259A/ja active Pending
- 2022-04-07 WO PCT/KR2022/005070 patent/WO2022216094A1/ko active Application Filing
- 2022-04-07 US US18/554,345 patent/US20240300928A1/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018183112A1 (en) * | 2017-03-27 | 2018-10-04 | Cardurion Pharmaceuticals, Llc | Heterocyclic compound |
KR20210020095A (ko) * | 2018-06-15 | 2021-02-23 | 화이자 인코포레이티드 | Glp-1 수용체 효능제 및 그의 용도 |
WO2020207474A1 (en) * | 2019-04-12 | 2020-10-15 | Qilu Regor Therapeutics Inc. | Glp-1r agonists and uses thereof |
WO2020263695A1 (en) * | 2019-06-28 | 2020-12-30 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
WO2021154796A1 (en) * | 2020-01-29 | 2021-08-05 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
WO2021187886A1 (ko) * | 2020-03-18 | 2021-09-23 | 주식회사 엘지화학 | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114630823A (zh) * | 2019-10-25 | 2022-06-14 | 吉利德科学公司 | Glp-1r调节化合物 |
US11897851B2 (en) | 2020-08-06 | 2024-02-13 | Gasherbrum Bio, Inc. | Heterocyclic GLP-1 agonists |
US11926626B2 (en) | 2020-08-28 | 2024-03-12 | Gasherbrum Bio, Inc. | Heterocyclic GLP-1 agonists |
US12091404B2 (en) | 2021-03-11 | 2024-09-17 | Gilead Sciences, Inc. | GLP-1R modulating compounds |
US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
WO2023111144A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2023111145A1 (en) | 2021-12-16 | 2023-06-22 | Astrazeneca Ab | Certain 3-azabicyclo[3.1.0]hexanes as glp-1 receptor modulators |
WO2024102625A1 (en) | 2022-11-11 | 2024-05-16 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
WO2024107781A1 (en) | 2022-11-16 | 2024-05-23 | Eli Lilly And Company | Glucagon-like peptide 1 receptor agonists |
Also Published As
Publication number | Publication date |
---|---|
JP2024514259A (ja) | 2024-03-29 |
US20240300928A1 (en) | 2024-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020384121B2 (en) | GLP-1 receptor agonist and use thereof | |
WO2022216094A1 (ko) | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 | |
WO2021187886A1 (ko) | Glp-1 수용체 효능제, 이를 포함하는 약학적 조성물 및 이의 제조방법 | |
AU2017374460B2 (en) | Novel phenyl propionic acid derivatives and uses thereof | |
EP4069686A1 (en) | Glp-1 receptor agonist | |
WO2017026718A1 (ko) | Ret 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-디]피리미딘-4-아민 화합물 | |
WO2017188694A1 (ko) | 질소를 포함하는 헤테로아릴 화합물 및 이의 용도 | |
WO2020096372A1 (ko) | 신규한 피페리딘-2,6-디온 유도체 및 이의 용도 | |
WO2018139903A1 (ko) | 피리미딘 화합물 및 그의 의약 용도 | |
WO2019078522A1 (ko) | 세레브론 단백질의 분해 유도 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2019074241A1 (ko) | 페닐아세틸렌 유도체를 포함하는 pd-1과 pd-l1의 상호작용 억제제 | |
WO2013105753A1 (en) | Substituted piperidine derivatives and methods for preparing the same | |
EP2989093A1 (en) | Novel triazolone derivatives or salts thereof and pharmaceutical composition comprising the same | |
WO2011122815A2 (en) | Novel quinoxaline derivatives | |
WO2023080652A1 (en) | Androgen receptor degraders for the treatment of castration-resistant prostate cancer and use thereof | |
WO2012111995A1 (en) | Oxime derivatives as gpr119 agonists | |
WO2015016511A1 (ko) | 신규한 바이페닐 유도체 및 그의 제조방법 | |
WO2010032986A2 (ko) | 신규 5-(4-아미노페닐)-이소퀴놀린 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 raf 키나제의 과활성에 의해 유발되는 질환의 예방 또는 치료용 조성물 | |
WO2021215624A1 (ko) | 신규의 2-아릴티아졸 유도체 또는 이의 염, 이의 제조방법, 및 이를 함유하는 약학 조성물 | |
WO2020017878A1 (en) | Novel catechol derivatives or salt thereof, processes for preparing the same, and pharmaceutical compositions comprising the same | |
WO2020101450A1 (ko) | 아질사르탄 유도체 화합물, 이의 중간체, 이의 제조방법 및 이를 포함하는 조성물 | |
WO2022164239A1 (ko) | 피라졸-카르복스아미드 유도체 화합물 및 이의 용도 | |
WO2024029877A1 (ko) | A3 아데노신 수용체 작용제로서의 신규한 퓨린 유도체 화합물 | |
WO2024035194A1 (ko) | 신규한 헤테로아릴 치환 유도체 및 이를 포함하는 신경퇴행성 질환, 암, 및 염증성 질환의 예방 또는 치료용 조성물 | |
WO2024014851A1 (ko) | Hif-1 단백질 억제제로서의 신규한 퓨린 유도체 화합물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22785003 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022785003 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023561836 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280026710.4 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2022785003 Country of ref document: EP Effective date: 20231005 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |